Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $28.7 million.

  • Whitehawk Therapeutics' Cash & Equivalents rose 432.47% to $162.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.6 million, marking a year-over-year increase of 432.47%. This contributed to the annual value of $28.7 million for FY2024, which is 54.41% down from last year.
  • Whitehawk Therapeutics' Cash & Equivalents amounted to $28.7 million in FY2024, which was down 54.41% from $62.9 million recorded in FY2023.
  • Whitehawk Therapeutics' Cash & Equivalents' 5-year high stood at $149.0 million during FY2021, with a 5-year trough of $4.5 million in FY2020.
  • Over the past 3 years, Whitehawk Therapeutics' median Cash & Equivalents value was $39.0 million (recorded in 2022), while the average stood at $43.5 million.
  • In the last 5 years, Whitehawk Therapeutics' Cash & Equivalents slumped by 88.44% in 2020 and then spiked by 3,244.31% in 2021.
  • Over the past 5 years, Whitehawk Therapeutics' Cash & Equivalents (Yearly) stood at $4.5 million in 2020, then spiked by 3,244.31% to $149.0 million in 2021, then slumped by 73.81% to $39.0 million in 2022, then surged by 61.17% to $62.9 million in 2023, then crashed by 54.41% to $28.7 million in 2024.